Definium Therapeutics (NASDAQ:DFTX) Shares Climb 7.5% – Here’s Why

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s stock price shot up 7.5% during trading on Friday. The stock traded as high as $37.11 and last traded at $36.74. Approximately 558,121 shares were traded during trading, a decline of 75% from the average session volume of 2,260,108 shares. The stock had previously closed at $34.18.

Analyst Upgrades and Downgrades

DFTX has been the subject of several analyst reports. Robert W. Baird raised their target price on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Bank of America started coverage on Definium Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price objective on the stock. Wall Street Zen downgraded shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $66.00 price target on shares of Definium Therapeutics in a research report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $66.00.

Definium Therapeutics Stock Up 8.3%

The firm has a market cap of $4.97 billion, a P/E ratio of -10.79 and a beta of 2.19. The stock’s 50 day simple moving average is $40.43 and its 200 day simple moving average is $32.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Research analysts anticipate that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Insider Buying and Selling

In other news, CEO Robert Barrow sold 31,550 shares of the firm’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the transaction, the chief executive officer owned 2,213,090 shares in the company, valued at $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of Definium Therapeutics stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the transaction, the chief financial officer directly owned 394,528 shares in the company, valued at approximately $14,427,888.96. The trade was a 0.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in shares of Definium Therapeutics by 28.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock worth $59,000 after buying an additional 343 shares during the last quarter. Nykredit A S bought a new stake in Definium Therapeutics during the second quarter worth $45,000. Allworth Financial LP purchased a new position in Definium Therapeutics in the second quarter worth $110,000. Integrated Wealth Concepts LLC purchased a new position in Definium Therapeutics in the second quarter worth $159,000. Finally, NewEdge Advisors LLC bought a new position in Definium Therapeutics in the 2nd quarter valued at $222,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.